The shift to a new era in Type 1 diabetes management

How can emerging disease-modifying therapies reshape the trajectory of type 1 diabetes?

In this episode, our host, Dr. Alice Cheng, discusses the cutting-edge landscape of type 1 diabetes (T1D) prevention and intervention with Dr. Bruce Perkins, endocrinologist, epidemiologist, clinician-scientist, and professor in the Faculty of Medicine and the Institute for Health Policy, Management and Evaluation at the University of Toronto.

Join our experts as they explore how T1D care is shifting from symptom management through insulin replacement toward early intervention in a disease that develops silently over years. Discover the clinical benefits of early disease modification and the transformative potential of novel therapeutic targets in delaying T1D onset and preserving beta-cell function. Learn about the practical mechanics of emerging therapies, where they precisely target the immune system, and how clinicians can take practical steps to screen, identify, and intervene before clinical symptoms or hyperglycemia present.

Tune in as we discuss the future of T1D care, exploring how population-wide screening and precision biomarker matching are actively bridging the critical gap between groundbreaking research and its clinical application.

Don't miss this discussion!

The opinions and views expressed in this episode are those of the speakers and do not necessarily reflect the position of the entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

Direct financial links, including receipt of fees: Abbott, Amgen, Aspen, Astellas, AstraZeneca, Bausch, Bayer, Biomea, Boehringer Ingelheim, Caliway Biopharmaceutics, Dexcom, Eisai, Eli Lilly, Gan & Lee, Insulet, HLS Therapeutics, Medtronic, Merck, MSD, Novo Nordisk, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MDBriefCase, LMC Physician Inc., Medscape, Humber River Health, TimedRight, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, American Diabetes Association, The Rounds, PeerVoice, Virtual Hallway, Diversified Canada. Advisory Committee or Speaker Bureau Members: Abbott, Amgen, Aspen, Astellas, AstraZeneca, Bausch, Bayer, Biomea, Boehringer Ingelheim, Caliway Biopharmaceuticals, Dexcom, Eisai, Eli Lilly, Gan & Lee, Insulet, HLS Therapeutics, Medtronic, Merck, MSD, Novo Nordisk, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Bruce Perkins:

Direct financial links, including receipt of fees: Abbott, Dexcom, Insulet NovoNordisk, Sanofi. Advisory Committee or Speaker Bureau Members: Abbott, Dexcom, Insulet, Nephris NovoNordisk, Sanofi, Vertex. Funded grants, research, or clinical trials: NIH-NIDDK, Diabetes Canada.

MAT-CA-2601068